Albany, NY (PRWEB) September 01, 2014
Vaccines can prevent and control infectious diseases, so the demand for these biological products is relatively rigid. In 2013, China’s human vaccine lot release volume grew by 4.9% from a year earlier, and the market size expanded 2.8% year on year. As vaccination is suspected of causing death and some companies (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) have to shut down the production of some products after failing to pass the new GMP certification, China's human vaccine market supply and demand may witness a slight decline in 2014, but it is still expected to grow steadily in the long run.
View Full Report at http://www.marketresearchreports.biz/analysis/220447
Affected by China’s economic level, national vaccine prevention policies and people’s awareness, free EPI vaccines prevail in China with a share of approximately 80% in the total lot release volume. Also, the Chinese health authorities are trying to improve the quality of EPI vaccines. For example, Huizhou City of Guangdong province takes the lead to contain poliomyelitis inactivated vaccines into its immunization program (Sanofi Pasteur acts as a supplier in this program) for a trial in 2014. However, this program stipulates the injection of the poliomyelitis inactivated vaccine “IPV” for the first two vaccinations, while requires the oral administration of the poliomyelitis attenuated vaccine “OPV” for the third and fourth vaccinations.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/220447
Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively.
The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China’s human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year.
Browse All China Market Research Reports http://www.marketresearchreports.biz/country/China
As China’s vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015.
Related Reports -
Global Influenza (Flu) Vaccine Market: Trends & Opportunities (2014-19)
View Full Report at http://www.marketresearchreports.biz/analysis/206965
The report titled “Global Influenza (Flu) Vaccine Market: Trends and Opportunities (2014-2019)” provides an insight into the market dynamics and various trends and opportunities associated with the global Influenza vaccine market. It covers the global market size and growth dynamics of the influenza vaccine market in past five years. The report further forecasts the market size for the coming five years along with factors that could influence the market dynamics in the projected period.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/206965
The report also captures the market share based on major players in the market. Further, the report also analyzes the domestic Influenza vaccine market of United States, Japan, Germany and United Kingdom. The report concludes with a brief discussion of key factors trending in the global influenza vaccine market and profiles major players like Sanofi, Abbott Laboratories, Novartis, CSL and Glaxo Smith Kline.
PharmaPoint: Meningococcal Vaccines - US Drug Forecast And Market Analysis To 2022
View Full Report at http://www.marketresearchreports.biz/analysis/170311
“PharmaPoint: Meningococcal Vaccines US Drug Forecast and Market Analysis to 2022”. Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines. Currently, tetravalent conjugate vaccines, such as Sanofi’s Menactra and Novartis’ Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.
Download Detail Report With Complete TOC at http://www.marketresearchreports.biz/sample/sample/170311
GlobalData expects growth in the meningococcal vaccines market to be primarily driven by the launch of serotype B vaccines, which address a critical unmet need in the treatment landscape. Vaccines that better protect infants and/or provide a longer duration of immunity also have an opportunity to seize market share during 2012-2022.
Marketresearchreports.biz is the most comprehensive collection of market research reports. Marketresearchreports.biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.